Emicizumab biosimilar (Wuhan Yzy Biopharma)

艾美赛珠单抗生物类似药（武汉友芝友）

Report date: 2025/12/29 09:41:29
First In Class

Base Information

Drug NameEmicizumab biosimilar (Wuhan Yzy Biopharma)
Drug Alias NameY225
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-Factor IXaAnti-Factor XBlood coagulation pathway activation
TargetsCoagulation factor XCoagulation factor IX
Therapy Area/IndicationsHemorrhageHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Yzy Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHubei Jiangxia LaboratoryWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsHemorrhageHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG